Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14842156 | 1.00 | RNPEP (0.44) | RNPEPALDH1A1NPSR1LMNACYP2C9 | |
| SCHEMBL15486553 | 0.86 | RNPEP (0.42) | RNPEPALDH1A1NPSR1LMNAFOLH1 | |
| SCHEMBL5544851 | 0.82 | RNPEP (0.42) | RNPEPALDH1A1NPSR1LMNAFOLH1 | |
| SCHEMBL14842225 | 0.81 | LMNA (0.34) | RNPEPLMNA | |
| SCHEMBL3587107 | 0.81 | LMNA (0.34) | RNPEPLMNA | |
| SCHEMBL5544831 | 0.81 | LMNA (0.34) | RNPEPLMNA | |
| SCHEMBL22722967 | 0.79 | PLA2G2C (0.45) | RNPEPALDH1A1NPSR1LMNAFOLH1 | |
| SCHEMBL22722965 | 0.79 | PLA2G2C (0.45) | RNPEPALDH1A1NPSR1LMNAFOLH1 | |
| SCHEMBL4284741 | 0.77 | CNR1 (0.41) | — | |
| SCHEMBL15304889 | 0.77 | MEN1 (0.54) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | RNPEP 4294/4885ALDH1A1 4310/4885NPSR1 21/4885 |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | RNPEP 863/4885ALDH1A1 27/4885NPSR1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.